BioCentury | Oct 13, 2020
Product Development

Oct. 13 Quick Takes: J&J pauses dosing in COVID-19 vaccine trials; plus Voyager, Avenue and Surface Oncology

...Avenue’s IV tramadolAvenue Therapeutics Inc. (NASDAQ:ATXI) received a complete response letter from FDA for IV tramadol...
BioCentury | Feb 7, 2020
Translation in Brief

Gilead’s remdesivir vs. 2019-nCov in cells; plus Syndax, Syntrix and Max Planck

...a January Frontiers in Pharmacology study . Desmetramadol is the active metabolite of the opioid tramadol...
BioCentury | Feb 1, 2020
Company News

Any chance left for safer opioids?

...for a drug that’s clearly less abused even if it isn’t as effective, and highlighted tramadol...
BioCentury | Jan 14, 2020
Company News

Amid need for new pain options, FDA panel rebuffs Nektar’s ‘safer’ opioid

...meetings are scheduled for three other pain therapies this week: a fixed dose combination of tramadol...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...data 3Q19 Revogenex Inc. / Fortress Biotech Inc. (NASDAQ:FBIO) / Avenue Therapeutics Inc. (NASDAQ:ATXI) IV tramadol...
BioCentury | Jun 13, 2019
Translation in Brief

Syntrix analgesic overcomes tramadol’s dependence on CYP2D6

...Bypassing the metabolic conversion required for Schedule IV opiate tramadol to achieve analgesia, Syntrix has positioned...
...to achieve analgesia, Syntrix has positioned desmetramadol as a safer and more effective pain therapy. Tramadol...
...as tramadol without the variability. According to Syntrix President, CEO and Founder John Zebala, both tramadol...
BioCentury | Apr 19, 2019
Clinical News

Pfizer, Lilly to mull anti-NGF mAb's future after joint safety events spike in long-term readout

...enrolled 3,021 patients who had inadequate pain relief from or intolerance to acetaminophen and either tramadol...
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

...BLA 2Q19 Revogenex Inc. / Fortress Biotech Inc. (NASDAQ:FBIO) / Avenue Therapeutics Inc. (NASDAQ:ATXI) IV tramadol...
BioCentury | Apr 6, 2018
Finance

Smid-cap smorgasbord

...date 6/30/18 Avenue Therapeutics Inc. (NASDAQ:ATXI) / Fortress Biotech Inc. (NASDAQ:FBIO) / Revogenex Inc. IV tramadol...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...Early 2018 Avenue Therapeutics Inc. (NASDAQ:ATXI) / Fortress Biotech Inc. (NASDAQ:FBIO) / Revogenex Inc. IV tramadol...
Items per page:
1 - 10 of 241